An independent index
Everyone is talking about peptides. Almost nobody is checking.
We read the research, grade how strong it actually is, and track what's legal where. Including — especially — when the honest answer is that nobody knows yet.
01 / The index
Every compound, graded.
One page per peptide, same format every time: what it is, what the studies show, how strong that evidence is, where it stands legally, and what remains unknown.
Approved, extensively trialled, and the reason most people heard the word "peptide" at all.
Human trialsApproved with large randomised trial data behind it for metabolic indications.
Human trialsEnormously popular for recovery and gut health. The published human trial data is close to nonexistent.
Animal onlyUsed widely for tissue repair on the strength of preclinical work and reported experience.
Animal onlyThe best-studied of the cosmetic peptides, mostly topical; injectable use is a different question.
Animal onlyHeavily marketed for energy and healthy ageing. Human outcome data remains thin.
Anecdotal02 / What we do differently
Three things nobody else maintains.
Evidence grade
A rating, not a vibe
Every compound carries the same three-tier grade — human trials, animal only, anecdotal. Applied consistently, explained openly, never softened because a compound is popular.
Status & rules
What's legal, where
Compounding status, regulatory reclassifications and jurisdiction differences, tracked as they change. The reference that doesn't exist anywhere else.
The lab
What's in the vial
How to read a certificate of analysis, what the mislabelling data shows, and what actually happens inside an unregulated supply chain.
03 / Dispatches
From the room, not the press release.
Conference coverage, regulatory decisions, and long-form interviews with the people who actually make, test and prescribe these compounds.
Status & rules · 9 August 2026
Six peptides cleared an FDA panel. None of them are legal to compound today.
The agency's advisory committee recommended six of seven peptides for the 503A bulks list. The headlines called it approval. It isn't — and the last substance to clear this committee on the same margin is still waiting, four years on.
Read the dispatch →
Disclosure
Who we are, and what we sell.
Peptide Curious is published by people who also work commercially in this field, including a peptide manufacturer and a telehealth practice. We think that makes the reporting more informed, not less — but you should know it, so it's stated here rather than buried.
Our rule: the Index describes research, never products. No compound page links to anything for sale. When we're writing about something we have a commercial interest in, we say so on the page.
Nothing here is medical advice, and nothing here is a recommendation to use any compound. We describe what studies have examined and how confident that evidence allows anyone to be. Dosing guidance is deliberately absent.